FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, namely to a humanized anti-PD-1 antibody and its antigen-binding fragment, as well as to a composition containing same. Also disclosed is a nucleic acid coding said antibody or its fragment, as well as a vector and a cell containing it.
EFFECT: invention is effective for treating a PD-1 mediated disease or condition.
12 cl, 5 dwg, 12 tbl, 16 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTI-PD-1 ANTIBODY AND USE THEREOF | 2017 |
|
RU2739610C1 |
| NEW ANTIBODY COMPOSITIONS FOR CANCER IMMUNOTHERAPY | 2019 |
|
RU2804490C2 |
| PROGRAMMED CELL DEATH (PD-1) PROTEIN-1 ANTIBODIES AND USE THEREOF | 2017 |
|
RU2725950C1 |
| ANTIBODY AGAINST TNFR2 AND ITS APPLICATION | 2020 |
|
RU2793165C1 |
| HUMANIZED ANTIBODY AGAINST PD-1 AND ITS USE | 2019 |
|
RU2803460C2 |
| ANTIBODIES AGAINST PD-L1 AND THEIR OPTIONS | 2017 |
|
RU2770590C2 |
| ANTIBODIES AGAINST OX40 AND THEIR USE | 2017 |
|
RU2783314C2 |
| BISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO PD1 AND LAG3 | 2018 |
|
RU2778805C2 |
| ANTIBODIES AGAINST LIGAND-1 PROGRAMMED DEATH (PD-L1) AND APPLICATION THEREOF | 2017 |
|
RU2721582C1 |
| ANTIBODIES AGAINST TNFRSF9 AND THEIR USE | 2019 |
|
RU2812200C2 |
